en Behavioral Neuroscience Behavioral Neuroscience Original Original <p dir="ltr" style="text-align:justify"><strong>Introduction</strong>: Clavulanic acid (CLAV) is structurally similar to ceftriaxone, a potent stimulator of glial GlutamateTransporter-1 (GLT-1) expression. The present study aims at exploring the anti-nociceptive effects of CLAV, a beta-lactamase inhibitor in rats underwent sciatic nerve Chronic Constriction Injury (CCI).&nbsp;<br> <strong>Methods</strong>: CLAV (12.5, 25, 50 mg/kg) was administered intraperitoneally after the surgery for 14 consecutive days. Behavioral pain parameters were evaluated before and 3, 5, 7, 10 and 14 days after injury. Spinal GLT-1 level was measured via western blotting at days 7 and 14.&nbsp;<br> <strong>Results</strong>: CCI led to mechanical allodynia, cold allodynia and thermal hyperalgesia which started on postoperative days 3 and continued until the end of study. We found that CLAV (12.5 and 25 mg/kg) significantly attenuated all pain related behaviors as compared to the CCI animals treated with normal saline. Protein level of GLT-1 was down-regulated on day 14 following CCI and this phenomenon was reversed by fourteen days treatment of CLAV at the low doses of 12.5 and 25 mg/kg.&nbsp;<br> <strong>Conclusion</strong>: These results suggest that CLAV might provide a new therapeutic strategy for neuropathic pain and its effect might be partially associated with the up-regulation of GLT-1.</p> Clavulanic Acid, Chronic constriction injury, Glutamate Transporter 1 345 354 http://bcn.iums.ac.ir/browse.php?a_code=A-10-799-2&slc_lang=en&sid=1 Bahareh Amin amin.bahareh@gmail.com 13700319475328460030744 13700319475328460030744 No Cellular and Molecular Research Center, Department of Physiology and Pharmacology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran. Mahmoud Avaznia mahmoodavaznia@gmail.com 13700319475328460030745 13700319475328460030745 No Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Reihaneh Noorani nouranir1@mums.ac.ir 13700319475328460030746 13700319475328460030746 No Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Soghra Mehri mehris@mums.ac.ir 13700319475328460030747 13700319475328460030747 No Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. ; Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Hossein Hosseinzadeh hosseinzadehh@mums.ac.ir 13700319475328460030748 13700319475328460030748 Yes Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. ; Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.